ArticleBJUI compass2026
The performance of prostate-specific antigen density in long-term prostate cancer-mortality risk prediction.
Article in BJUI compass, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The objective of this study is to examine whether a baseline calculation of PSAD is associated with prostate cancer-specific mortality after 30 years of follow-up. Methods: One-thousand seven-hundred and seventy-nine men were screened for prostate cancer with a PSA test, digital rectal exam (DRE) and ultrasound of the prostate (TRUS). Outcomes, that is, prostate cancer-specific mortality, were extracted from the Swedish National Cause of Death Registry. Hazard ratios for cancer-specific deaths were estimated using Cox proportional hazard regression model. The area under the receiver operating curve (AUC) was determined using logistic regression for men with a baseline PSA in the interval between 3.0 and 10.0 ng/ml. Results: PSAD was available for 1748 men. Median PSAD was 0.095 ng/ml/cm Conclusions: For men with PSA between 3 and 10 ng/ml, PSAD is a predictor of the long-term risk for lethal prostate cancer. One limitation to this study is the lack of clinical data during follow-up apart from cancer-specific mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.